Drugs / HCB101
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05892718 | Oct 2023 → May 2027 expected | non-Hodgkin lymphoma | FBD Biologics Limited | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07136545 | Aug 2025 → Dec 2026 expected | head and neck squamous cell carcinoma | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07204574 | May → Dec 2025 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCB101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05892718 ↗ |
| Modality | Protein / enzyme biologic | “Fc-fusion Protein Targeting SIRPα-CD47 Pathway” NCT05892718 ↗ |
| Route | Intravenous | “HCB101 administered via. intravenous (IV) infusion.” NCT05892718 ↗ |